Adaptive Biotechnologies president and COO Julie Rubinstein sells $954k stock
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $ADPT +4.29% in the latest session.
- Timing: Filed after the close: the price beside it finished its day before the story existed, so the next session gets the first real vote.
Where the stock stands
$ADPT last traded at $27.98, +4.29% on the session. That puts it 9.0% shy of its 52-week high of $30.74 and 133% clear of its low of $12.00 — in the upper part of the range. Over the year it has ranged 156% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $ADPT page.
How much coverage it is getting
Wook has logged 2 stories on $ADPT in the last 30 days, 1 of them this week. At its 30-day pace you would expect less than one a week, so this week is running well ahead of normal; the press has found a reason to keep writing. Across those stories 0 read bullish, 2 neutral and 0 bearish — mostly headline writers keeping a straight face. This one reads neutral, so it sits squarely with the crowd. 2 of the 2 (100%) came from Investing.com itself, so the count says as much about how often Investing.com hits publish as about how much attention there is — the other outlets are the better gauge. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
What to watch next
For the receipts, the $ADPT page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $ADPT is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ADPT. It carried $954K, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.